Jazz Pharmaceuticals PLC (JAZZ)

Gross profit margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Gross profit (ttm)	US$ in thousands	1,857,966	1,795,547	1,590,622	1,545,199	1,419,171	1,286,756	1,295,802	1,064,367	1,021,917	1,387,832	1,630,995	1,976,019	2,197,743	2,127,775	2,073,842	2,039,394	2,007,671	1,907,490	1,845,192	1,810,826
Revenue (ttm)	US$ in thousands	3,809,836	3,720,411	3,685,651	3,662,251	3,569,427	3,471,828	3,371,195	3,194,350	2,999,693	2,864,101	2,628,980	2,436,329	2,361,556	2,277,779	2,214,357	2,184,676	2,158,500	2,053,217	1,985,763	1,953,884
Gross profit margin		48.77%	48.26%	43.16%	42.19%	39.76%	37.06%	38.44%	33.32%	34.07%	48.46%	62.04%	81.11%	93.06%	93.41%	93.65%	93.35%	93.01%	92.90%	92.92%	92.68%

December 31, 2023 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $1,857,966K ÷ $3,809,836K
= 48.77%

The gross profit margin of Jazz Pharmaceuticals plc has shown a consistent and generally positive trend over the past eight quarters. It increased from 85.23% in Q4 2022 to 88.64% in Q4 2023, indicating a strengthening ability to generate profit from sales after accounting for the cost of goods sold. This trend suggests effective cost management and pricing strategies that have been improving the company's profitability. The overall picture is one of operational efficiency and financial health, with a steady upward trajectory in the gross profit margin, reflecting well on Jazz Pharmaceuticals' performance in generating profits from its core business activities.